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Abstract Mammography has been found effective as the
primary screening test for breast cancer. We estimated the
cumulative probability of false positive screening test
results with respect to symptom history reported at screen. A
historical prospective cohort study was done using indi-
vidual screening data from 413,611 women aged
50–69 years with 2,627,256 invitations for mammography
screening between 1992 and 2012 in Finland. Symptoms
(lump, retraction, and secretion) were reported at 56,805
visits, and 48,873 visits resulted in a false positive mam-
mography result. Generalized linear models were used to
estimate the probability of at least one false positive test and
true positive at screening visits. The estimates were com-
pared among women with and without symptoms history.
The estimated cumulative probabilities were 18 and 6 % for
false positive and true positive results, respectively. In
women with a history of a lump, the cumulative probabili-
ties of false positive test and true positive were 45 and 16 %,
respectively, compared to 17 and 5 % with no reported
lump. In women with a history of any given symptom, the
cumulative probabilities of false positive test and true pos-
itive were 38 and 13 %, respectively. Likewise, women with
a history of a ‘lump and retraction’ had the cumulative false
positive probability of 56 %. The study showed higher
cumulative risk of false positive tests and more cancers
detected in women who reported symptoms compared to
women who did not report symptoms at screen. The risk
varies substantially, depending on symptom types and
characteristics. Information on breast symptoms influences
the balance of absolute benefits and harms of screening.
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Introduction
Organized screening programs for breast cancer have been
estimated to reduce breast cancer mortality by about 23 %
among those invited. On the other hand, however, it has
also been shown to increase the risk of cumulative false
positive results by about 20 % [1]. These estimates
describe mainly screening programs that invite women
aged 50–69 or 50–74 years. There is no clear evidence on
effectiveness of systematic clinical breast examination
without mammography or of breast self-examination [1, 2].
In addition to sole mammography as the screening test,
some programs or trials have performed clinical or physical
examination [3]. Clinical examination means systematic
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palpation by specifically trained staff [3]. However, the
clinical examination in Finland is done by collecting self-
reported information on symptoms during the screening
examination as well as inspection of breasts by the
radiographer.
Self-reported symptoms as well as radiographer
reports on observations have been a part of the mam-
mography screening program in Finland, since the pro-
gram started in the late 1980s [3, 4]. Cross-sectional
studies have indicated that symptoms have important
consequences on the performance of screening [5–7].
There is a risk that harms of screening may increase, as
information on symptoms launch further assessments not
dealing with breast cancer. The findings of the physical
examination may also relate to long-term patterns over
several screening rounds.
The main purpose of this study was to estimate the
cumulative probability of false positive mammography
tests and true positives in women’s visits with symptoms,
compared with those visits with no reported symptoms at
mammography screening in the Finnish programme in
women aged 50–69 years. In addition, we estimated the
risk of false positive test and true positive with accumu-
lated same symptom or any symptoms in the screening
history.
Materials and methods
Study design, setting, and data source
The current study is a register-based cohort study, which
utilizes the screening visit history of women who attended
the mammography screening program in Finland. The
program invited women aged 50–69 years every second
year for mammography screening in special organized
clinics. Information on breast cancer screening has been
registered at the Mass Screening Registry which is part of
the Finnish Cancer Registry. The women were asked about
breast symptoms at the visit. Any symptoms (lump,
retraction, secretion, mole, and scar) women had during the
past 2 months were recorded on the mammography form
(http://www.cancer.fi/@Bin/44068785/Mammography?
form_2006.pdf). The mammography screening examina-
tion was two-view for both breasts. The detailed
mammography screening process has been described ear-
lier [5]. The registration coverage increased with time,
from 51.2 % in 1992 to 90 % in 1998 and virtually 100 %
in 2005 and afterwards [4].
The current study population included 413,611 women
who were invited for the first time at age 50–51 years in
1992–2004 and were followed up until 2012. Altogether,
2,627,256 invitations were identified during the period
1992–2012, out of which 2,283,706 (87 %) visits were
made with an average of 5.5 visits per woman. Records
with missing data on symptoms were excluded from the
analysis (Table 1). The maximum number of visits per
woman was 10, and visits exceeding 10 (145 visits) due to
migration within the country were excluded from the cur-
rent analysis.
Definition of variables
Test positives are those with primary mammography pos-
itive—they are recalled for further assessment (often more
mammograms, ultrasound, and needle biopsy) at the
screening clinic, if the mammogram indicated any abnor-
mality. The assessment part is called an episode and those
with a positive episode are referred to hospital for diag-
nostics/treatment. Test positives may be episode negative
(no referral) or episode positives (referred) and those who
are then diagnosed with cancer are true positives at all
stages. False positive test are those with negative episode
or with a positive episode but no cancer diagnosis at hos-
pital. False positive mammography tests were further
classified as at least one or first false positives depending
on the screening history: ‘at least one’ if a woman was
detected as false positive at any given screening visit
irrespective of earlier visit findings and ‘first’ if a woman
was detected as false positive at any given screening visit
given that mammography in all previous visits was nega-
tive. False positive referrals are those with episode positive
but no cancer diagnosis in hospital. The average number of
visits per woman was defined as the total number of visits
made at ages 50–69 years divided by the number of women
screened during that period of age. Number of invitations
per woman was counted as the number of subsequent
invitations a woman received after the first invitation at age
50–51 years.
Women with symptoms reported either by the woman
herself or by the radiographer were considered as symp-
tomatic. Symptoms history variable for either lump or
retraction or secretion, was created and defined as symp-
toms reported ever before or at the index visit. Here, index
visit means the visit that resulted in a positive test result
(either false positive test or true positive test). The possi-
bility of reporting more than one symptom at a single
screening visit was also considered. For that, combinations
of two symptoms at a time were made as ‘none,’ ‘either’
and ‘both.’ Separate variables for each symptom reported
once or more than once in the screening history were
created and coded as ‘1 time’ and ‘more than 1 time.’ A
separate variable on the absolute number of visits (1–10)
per woman was created to compare the probability of false
positive test by screening visits, overall versus those with
symptoms history.
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Statistical analysis
Lump, retraction, and secretion, the most clinically rele-
vant symptoms, were used for analysis. Let i be the index
subjects i = 1,…, n and j be the index visits of ith subject
j = 1,…, Ji. We note by P(Yij = 1; Xij) the probability of a
false positive test for subject i at the jth screen given
covariates Xij. The cumulative risk of first outcome event
after k rounds of screening is qk ¼ 1 
Qk
j¼1 1  PðYij ¼

0; Yi j1ð Þ ¼ 0; . . .; Y1 ¼ 0Þg [8]. Applying discrete-time
hazard model with logit PðYijÞ
  ¼ X 00ijb an estimator for
cumulative risk can be obtained. A standard logistic
regression can be used to get an estimate of the logistic
regression model parameters. Suppose that subject i had
symptoms at the lth attended visit. For each subject i the
visits can be divided into non-symptomatic j = 1,…, l-1
visits and symptomatic visits j = l,…, J starting from the
first symptomatic visit: yij;Xij ¼ 0
 
; i ¼ 1; . . .; I; j ¼
1; . . .; l 1g and yij;Xij ¼ 1
 
; i ¼ 1; . . .; I; j ¼ l; . . .; J .
Cumulative risk of false positive test and true positive
(cancer diagnosis) was estimated as shown above. General-
ized linear regression (GLM) model in R statistical software
was used to estimate the effect of an individual symptom as
well as combined symptoms on the false positive and true
positive probabilities. Confidence intervals at 95 % were
estimated using approximate Bayesian inference (INLA) [9].
Results
In 56,805 (2.5 %) visits at least one symptom was reported
during the study period in 1992–2012 with a maximum
follow-up of 21 years. A lump was reported in 26,145
(1.22 %) visits, retraction in 26,653 (1.59 %) visits, and
secretion was reported in 5325 (0.24 %) visits (Fig. 1).
There were combined symptoms, as well, with both lump
and retraction at 557 visits, lump and secretion at 572
visits, and retraction and secretion at 207 visits. Overall,
48,873 visits (2.1 %) out of total visits had false positive
tests. Of these, 44,541 false positive tests were confirmed
one time and 4332 false positive test were confirmed more
than one time in women screening history. The false pos-
itive test percentage at a given visit was 7.2 % (4063 visits)
in women with symptoms compared to 2.0 % (44,810
visits) in women with no symptoms. Similarly, the true
positive (breast carcinoma) percentage was 2.2 % (1230
visits) in women who reported symptoms compared to
0.4 % (9718 visits) in women with no symptoms (Fig. 1).
The percentage of women who reported a lump or
secretion was higher in younger age groups compared to
the older age groups (lump = 1.71 vs. 0.78 %; secre-
tion = 0.32 vs. 0.04 % at 1st and 10th visit, respectively)
(Table 1). The false positive proportion among women
who reported any symptoms was significantly higher at
every visit (order, 1–10) compared to those who did not
report any symptoms, overall 7.2 vs. 1.5 %, respectively.
False positive test probability based on the absolute num-
ber of woman’s visits showed similar difference in women
with symptom history compared to women with no history
of symptoms (Fig. 2). However, false positive test proba-
bility was lower in women who had less (absolute) number
of visits compared to those who had completed all possible
(ten visits) screening visits. Similarly, the false positive
referral and true positive proportions were higher among
women who reported symptoms versus no reported symp-
toms, 2.8 vs. 0.6 % and 2.2 vs. 0.4 %, respectively.
Fig. 1 Flow diagram of mammography screening program by symptom status
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Table 2 shows the at least one cumulative false positive
test and true positive probability after 10 visits. The cumu-
lative probabilities of at least one false positive test, false
positive referral, and true positive were 18.2, 1.5, and 5.7 %,
respectively, after 10 visits. The cumulative probability of
first false positive test was 15.9 % (not shown in Table).
The cumulative probability of having at least one false
positive test was significantly higher in those who had a
history of lump compared to those with no history of lump,
45.2 vs. 17.2 % estimated for 10 visits. Cumulative proba-
bility of at least one false positive referral and true positive in
women who reported any symptoms in screening history
Fig. 2 False positive (FP) test probability; overall (i) and any symptoms (ii), by attended number of screening visits of women















1 0.0407 0.0407 0.0034 0.0034 0.0047 0.0047
2 0.0216 0.0614 0.0014 0.0048 0.0037 0.0084
3 0.0187 0.0790 0.0013 0.0061 0.0042 0.0125
4 0.0167 0.0944 0.0010 0.0071 0.0045 0.0170
5 0.0159 0.1089 0.0010 0.0081 0.0053 0.0222
6 0.0154 0.1226 0.0011 0.0092 0.0060 0.0281
7 0.0149 0.1357 0.0011 0.0103 0.0065 0.0344
8 0.0141 0.1479 0.0010 0.0113 0.0069 0.0411
9 0.0174 0.1627 0.0015 0.0128 0.0076 0.0483
10 0.0224 0.1822 0.0024 0.0151 0.0090 0.0569
Bold numbers indicate the final cumulative number
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were 3.8 and 12.6 %, respectively, compared to 1.4 and
5.3 %, in women with no history of any symptom. (Table 3)
There was some increase in the probability of false positive
test before the visit with a lump compared to visits with no
lump, though true positive probability did not differ (see
supplementary table, S1). Women who reported lump or
secretion more than one time had higher cumulative proba-
bility of at least one false positive test than women who
reported lump or secretion once in screening history, 47.8 vs.
44.0 % for lump and 39.8 vs. 33.4 % for secretion, respec-
tively. However, cumulative probability of true positive was
lower in women who reported symptoms more than one time
compared to one time in screening history.
The cumulative false positive probability in women who
reported ‘lump and retraction’ was higher, 56.5 % (95 % CI
47.4–66.3) compared to those who did not report either
symptom, 17.1 % (95 % CI 16.6–17.7) (Fig. 3). For Women
who reported ‘lump and secretion, the cumulative false
positive test probability was 54.8 % (95 % CI 45.3–69.6).
Discussion
Our study found significantly higher cumulative false
positive test and true positive probability among those who
reported symptoms at screen compared to those who did
not report any symptoms. The cumulative risk of false
positive test (after 10 rounds) with any symptom was 38 %
and that without was 17 %. Lump was associated with the
highest cumulative false positive risk of 45 %, retraction
25 %, and secretion 35 %.
The overall cumulative probability of at least one false
positive test was 18 % after 10 screening visits at age
50–69 years and the false positive test probability was
3.6 % at the first visit at age 50–51 years. Our results are
consistent or somewhat lower with that of previous studies
from other European countries [10–17]. A study from
Norway reported a higher cumulative false positive risk
(23 %) than the current study [10]. Another study esti-
mated a 21 % cumulative false positive probability pro-
jected after 10 screening visits, based on the results of three
consecutive screening visits performed in four counties
[11]. A retrospective cohort study from Spain projected the
cumulative false positive risk to be 20.4 % after 10
screening visits [12]. Cumulative false positive probability
from a randomized trial in the UK (2010) was 20.5 % over
seven screening rounds [16]. A Danish study [14] made the
prediction, based on 3–5 observed screening rounds, of
cumulative false positive test probability slightly lower
than that of our study. However, the false positive test
probability at first screen was higher (5.7 %) in Copen-
hagen than that of the current study. In the Netherlands,
Otten et al. (2013) found lower cumulative false positive
risk after 13 consecutive screening examinations than that
of our study, but they expected higher estimates after
digital mammography was introduced in 2003 [18, 19].
Nonetheless, there were some variations between countries
in the methodology and health service system, such as age
at first invitation [10, 14, 18], projected estimates based on
few observed rounds [11, 18], and lower recall proportion
of\1 % at subsequent screens [18, 20] compared to 2.2 %
in our study and\3 % in European guidelines [21], while
estimating the false positive risk.
Studies conducted in the USA have reported much
higher risk of cumulative false positive tests than that of the
current study [8, 22–25]. In the US, Breast Cancer
Surveillance Consortium (BCSC) data from all women
(n = 88,455) first screened at age 50-69 years between
1996 and 2010 estimated the cumulative false positive risk
to be 41.9 % after eight screens annually or biennially [24].
The reason for lower estimates in our study may be due to
different program organizations in Finland than in USA as
well as variation in age at first screening, definitions of
recall, recording and coding of screening data, screening
interval, etc. [26]. Also, the European quality standards
[21] are adequately met by the Finnish screening program.
Together with the cumulative probability of ‘at least
one’ false positive, this study also estimated the cumulative
‘first’ false positive test and true positive probability. The
Table 3 Cumulative probability of at least one false positive (FP)
















Yes 0.4516 0.0332 0.1630
1 time 0.4401 0.0357 0.2002
[1 time 0.4780 0.0268 0.0650
No 0.1721 0.0146 0.0531
Retraction
Yes 0.2464 0.0261 0.0903
1 time 0.2662 0.0429 0.1868
[1 time 0.2342 0.0159 0.0368
No 0.1807 0.0204 0.0567
Secretion
Yes 0.3477 0.0789 0.0638
1 time 0.3339 0.0677 0.0691
[1 time 0.3981 0.1239 0.0489
No 0.1811 0.0146 0.0569
Any symptom
Yes 0.3843 0.0377 0.1262
1 time 0.3938 0.0422 0.1730
[1 time 0.3694 0.0315 0.0533
No 0.1699 0.0138 0.0530
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cumulative first false positive probability was 16 % as we
considered only the first false positive mammography
result, excluding later false positive findings of the same
woman. Hence, the estimate is lower than the ‘at least one’
false positive estimate. Also, the lower probability of false
positive in our study may be due to the exclusion of the first
visits made at later age, hence removing contamination of
newcomers at later visits with prevalent screens. Our study
estimated the cumulative true positive probability to be
6 % after 10 screening visits. A study in the Netherlands
estimated similar cumulative cancer detection risk after 13
consecutive screening examinations [18]. We are not aware
of other studies on cumulative true positive estimates after
10 screening visits.
No prior studies have estimated the cumulative proba-
bility based on reported symptoms with a complete follow-
up information. Women who reported having symptoms,
especially lump and secretion at screening visit, current or
at any previous visit, were significantly more likely to have
a false positive test and true positive result than women
with no symptoms reported. The cumulative false positive
probability in women with a history of lump was 45 %
compared to 17 % with no lump. When considering the full
visit history of women with lump, before and after visit
with lump, the higher probability of false positive test
before the visit with a lump indicates that there was a
possibility that some unspecific changes in the
mammograms had been seen even several years before the
visit when a lump was reported. On the other hand, after
reporting the first symptom there was no increase in the
probability of false positive test and true positive results in
the later visits. This means that woman was treated and no
cancer was detected in later visits. Women were more
likely to be true positive if they reported symptoms at
screen; cumulative true positive probability of 16 % was
compared to 6.5 % with no reported lump. Similarly,
women who reported both ‘lump and retraction’ in the
same visit had cumulative false positive test probability of
56.5 % (95 % CI 47.4–66.3) compared to 17.1 % (95 % CI
16.6–18.3) without symptoms. Similar results were found
in women with other possible combination of symptoms.
Taking into account the information on breast symptoms,
there is a concern for the radiologist whether or not to
recall the symptomatic women. Also, variation in the false
positive probability by symptom status, number of times
symptom was reported, shows that not all symptoms are
equally sensitive. At the same time, the findings also
showed benefits of evaluating symptoms information on
the performance (more cancers detected) of mammography
screening program.
One of the limitations of this study is the missing
information on some important risk factors such as hor-
mone use, breast density, and family history of breast
cancer, while estimating the cumulative false positive and
Fig. 3 Cumulative probability of at least one false positive (FP) test among women reported symptoms at screen
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true positive probability in relation to symptoms. The
missing information (1.2 % of total visits) on symptoms
was due to incomplete reporting by some centers in the
early years of the program. Women recalled but not
referred to hospital and women referred but with no cancer
in histological confirmation who may have had a cancer
before the next screening visit (interval cancer), were not
taken into account in this study. Other performance mea-
sures of screening program, including interval cancers and
mortality as stated by Otten et al. [18] and Tornberg et al.
[27], in relation to breast symptoms need to be evaluated
thoroughly.
The current study is based on a large nationwide
screening cohort with complete follow-up of the women
up to maximum 10 visits (21 years). The high partici-
pation rate ([85 %) in the screening program and few
opportunistic screening means false positive probability
estimates over the 10 screens equals the lifetime risk of
false positive test in Finland, which is similar to that
reported by a Danish study [14]. The radiologists
learning of the previous mammography results and the
small difference between ‘at least one’ and ‘first’
cumulative probability estimates form the basis to con-
clude independence between false positive risks at sub-
sequent screen.
In conclusion, the current study showed that information
about breast symptoms, especially lump, cause harms in
terms of extra false positive findings. The risk varies sub-
stantially, depending on symptom types and characteristics.
At the same time, more cancers were detected in symp-
tomatic women suggesting benefits of evaluating symptoms
information in the program. Information on breast symp-
toms influences the balance of absolute benefits and harms
of screening for the individual woman, and should be
considered carefully in breast cancer screening programs.
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